Table 6.

Comorbidities of the study population 2015–2019 without and with COVID-19 ICU admission (Feb 2020–Dec 2021)

Diagnosis (group)	Control group without COVID- ICU admission (N = 39,190)		Treatment group with COVID- ICU admission (N = 7,838)		COVID/non-COVID
	N	Share (%)	N	Share (%)	RR	p-value
Hemiplegia or paraplegia	251	0.5	68	2.6	5.23	0.09	*
Diabetes with complications	1,331	1.4	655	4.5	3.22	0.00	***
Renal disease	2,505	2.6	1,091	7.8	3.00	0.00	***
Moderate or severe liver disease	180	0.2	64	0.6	2.84	0.00	***
AIDS/HIV	25	0.1	5	0.2	2.69	1.00	–
Diabetes without complications	4,154	5.0	1,534	13.2	2.66	0.00	***
Mild liver disease	1,759	2.5	574	6.7	2.65	0.00	***
Chronic obstructive pulmonary disease	2,789	4.1	998	9.7	2.40	0.00	***
Congestive heart failure	2,503	2.6	886	6.0	2.33	0.00	***
Rheumatoid disease	428	0.7	151	1.4	2.17	0.00	***
Peripheral vascular disease	2,579	2.5	820	4.7	1.83	0.00	***
Acute myocardial infarction	1,283	1.5	353	2.3	1.55	0.00	***
Cerebrovascular disease	3,465	3.8	892	5.5	1.43	0.00	***
Peptic ulcer disease	437	0.6	113	0.9	1.41	0.07	*
Cancer (any malignancy)	4,014	4.9	786	6.2	1.25	1.00	–
Metastatic solid tumour	648	0.8	93	0.8	1.00	0.01	**
Dementia	1,039	1.1	155	0.9	0.83	0.00	***
CCI >=5	2,281	2.4	827	5.3	2.22	0.00	***
CCI 3–4	3,245	3.4	1,044	9.0	2.62	0.00	***
CCI 1–2	10,013	14.8	2,357	25.5	1.72	0.00	***
CCI 0	23,651	79.4	3,610	60.2	0.76	0.00	***

Authors’ calculation based on [16, 17]

*, **, *** refer to significance at the p < 0.10, p < 0.05, and p < 0.01 level, respectively. Age-standardized and sex-standardized shares and risk ratios based on the Austrian population 2020; p-values refer to χ2-tests, where the family-wise error rate is controlled for with the Holm method

CCI Charlson comorbidity index, RR relative risk, ICU intensive care unit